Clinical Trials Logo
  1. Home
  2. Hepatocellular Carcinoma (HCC)
  3. NCT01247298

A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma — RAD 0902  

Hepatocellular Carcinoma (HCC) Clinical Trial

Official title:
RAD 0902: A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma

Clinical Trial Summary

This investigational study will evaluate if using a combination of TACE along with high dose SBRT would show improvement in local control in patients with Hepatocellular Carcinoma.

Clinical Trial Description

Primary objectives of this research

1. Evaluate the safety of a combination of TACE and high dose SBRT

2. Measure time to progression (TTP) and local recurrence rate of HCC treated with a combination of TACE & SBRT.

Secondary objectives of this research

1. Assess failure patterns and survival of patients treated with TACE & SBRT.

2. Analyze dose volume characteristics that influence Radiation Induced Liver Disease (RILD) among patients treated with a combination of TACE and SBRT. ;

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01247298
Study type Interventional
Source University of Alabama at Birmingham
Contact
Status Completed
Phase Phase 0
Start date October 2010
Completion date December 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT03007212 - Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Phase 4
Terminated NCT03236649 - The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects Phase 3
Withdrawn NCT04044326 - The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors N/A
Recruiting NCT04687969 - Multimodal Machine Learning Characterization of Solid Tumors
Completed NCT02562755 - Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Phase 3
Withdrawn NCT02406508 - Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC Phase 2
Completed NCT01972672 - The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma Phase 2
Completed NCT03735628 - An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Phase 1
Completed NCT02188901 - Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study N/A
Active, not recruiting NCT04522908 - Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function Phase 2
Terminated NCT01433016 - Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI Phase 2
Withdrawn NCT04465734 - A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC Phase 3
Recruiting NCT05057013 - HMBD-001 in Advanced HER3 Positive Solid Tumours Phase 1/Phase 2
Active, not recruiting NCT03753659 - IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) Phase 2
Terminated NCT03144661 - An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Phase 1
Not yet recruiting NCT01821482 - A Study of DC-CIK to Treat Hepatocellular Carcinoma Phase 2
Completed NCT03516071 - A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC Phase 2
Completed NCT01761266 - A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Phase 3
Not yet recruiting NCT06345001 - A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer Phase 1
Completed NCT02794805 - Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis Phase 2